ARTICLE | Clinical News
Labetuzumab-SN-38: Phase II started
August 19, 2013 7:00 AM UTC
Immunomedics began an open-label Phase II trial to evaluate IMMU-130 given every 2 weeks for 24 weeks in about 50 patients with metastatic colorectal cancer who have been previously treated with >=1 p...